The Ivis Spectrum CT for Pre-Clinical Oncology Research
The Ivis Spectrum CT for Pre-Clinical Oncology Research
批准号:
8446658
负责人:
PAT B ZANZONICO
金额:
$59.46万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-20 至 2014-08-19
关键词:
6 year oldAnatomyAnimalsBackBiological SciencesBiomedical ResearchClinical OncologyCore FacilityDiseaseFailureFunding ApplicantGeneticImageImmuneInterventionLaboratoriesLightingLongevityMalignant NeoplasmsMemorial Sloan-Kettering Cancer CenterModelingMonitorMusOptical TomographyOpticsPathway interactionsProcessRattusResearchResearch InfrastructureResolutionServicesSignal TransductionStem cellsSystemThree-Dimensional ImagingWorkX-Ray Computed Tomographybasefluorescence imagingin vivoinstrumentoncologyphotonicspre-clinicalprogramsresponsetraffickingtumor
中文摘要
描述(由申请人提供):申请资金用于购买Ivis光谱CT光学和计算机断层扫描(CT)成像系统(马萨诸塞州霍普金顿市Caliper生命科学公司),用于体内生物光子(即生物发光和荧光)定量成像,用于无创和纵向监测(a)癌症和其他疾病过程,(b)癌症、免疫和干细胞的贩运,(c)细胞对治疗和其他干预措施的反应。(d)遗传通路在小动物(即小鼠和大鼠)肿瘤模型中的表达。就像我们现有的两个Ivis系统,Ivis 100和Ivis 200一样,这个最先进的仪器,将安装在我们的小动物成像核心设施中,将成为纪念斯隆-凯特琳癌症中心(MSKCC)临床前和转化肿瘤学研究项目的关键,广泛使用的组成部分。体内生物发光和荧光成像已迅速成为世界范围内临床前生物医学研究的主要内容。然而,我们的Ivis 100和200系统的使用非常频繁(现在已经超出了容量),并且它们的使用还在继续增加-它们是迄今为止使用最多的小动物成像仪器,支持整个MSKCC多达36个实验室。因此,不存在备份/冗余。因此,当其中一个系统需要服务时,实验工作就会延迟,甚至可能受到损害,甚至丢失。此外,Ivis 100和Ivis 200现在分别是9岁和6岁,接近或已经超过其使用寿命,因此随时可能出现无法挽回的故障。除了提供急需的额外成像能力和备份之外,Ivis光谱CT还将提供关键的新功能,包括:(1)光学和近红外(NIR)范围内的跨照明荧光成像,提供更好的光谱分辨率和荧光成像对比度;(2)三维(3D)/层析成像能力,提供关键深度信息;(3)集成基于ct的三维成像,实现光学图像和解剖图像的近乎完美的无缝配准,从而实现光信号焦点在体内的明确定位。我们的基金和中心拥有完善的技术和科学专业知识,可以在该工具安装后充分和立即利用该工具,并拥有高效的行政和财务基础设施,以支持和维护该工具及其长期有效使用。
英文摘要
DESCRIPTION (provided by applicant): Funds are requested to purchase an Ivis Spectrum CT optical and computed tomography (CT) imaging system (Caliper Life Sciences, Hopkinton, MA) for quantitative in vivo bio photonic (i.e. bioluminescent and fluorescent) imaging for non-invasively and longitudinally monitoring (a) cancer and other disease processes, (b) trafficking of cancer, immune, and stem cells, (c) cellular responses to therapy and other interventions, and (d) genetic pathway expression in small-animal (i.e. mouse and rat) tumor models. Like our two existing Ivis systems, the Ivis 100 and 200, this state-of-the-art instrument, to be installed n our Small-Animal Imaging Core Facility, will be a critical, broadly used component of the pre-clinical and translational oncology research program at Memorial Sloan-Kettering Cancer Center (MSKCC). In vivo bioluminescent and fluorescent imaging has rapidly become a staple of pre-clinical biomedical research world-wide. However, both our Ivis 100 and 200 systems are used very heavily (and, now beyond capacity) and their use continues to increase - they are by far the most heavily used of our small-animal imaging instruments, supporting up to three dozen laboratories throughout MSKCC. Thus, there is no back-up/redundancy. When one of these systems requires service, therefore, experimental work is delayed and potentially compromised and even lost. Further, the Ivis 100 and 200 are now 9- and 6-years-old, respectively, and approaching or already beyond their useful lifespan and thus subject to irreparable failure at any moment. Besides providing urgently needed additional imaging capacity and back-up, the Ivis Spectrum CT would provide critical new functionality, including (1) trans-illumination fluorescence imaging in both the optical and near-infrared (NIR) range, providing far better spectral resolution and fluorescence-imaging contrast; (2) three-dimensional (3D)/ tomographic imaging capability to provide critical depth information; and (3) integrated CT-based 3D imaging to allow seamless near-perfect registration of optical and anatomic images and thereby unambiguous localization in vivo of optical signal foci. Our Facility and Center have well-established technical and scientific expertise to fully and immediately utilize this instrument upo its installation and an efficient administrative and financial infrastructure to support and maintan this instrument and its effective use long-term.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/acs.molpharmaceut.7b01133
发表时间:
2018-06-04
期刊:
Molecular pharmaceutics
影响因子:
4.9
作者:
[Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, Larson SM, Carrasquillo JA]
通讯作者:
Carrasquillo JA
The X-Rad SmART+ Biological Irradiator for Pre-Clinical Oncology Research
-
批准号:10175157
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2021
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:8961776
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2015
-
负责人:PAT B ZANZONICO
-
依托单位:
The Inveon PET/CT for Pre-Clinical Oncology Research
-
批准号:8334760
-
项目类别:
-
资助金额:$102.78万
-
财政年份:2012
-
负责人:PAT B ZANZONICO
-
依托单位:
NanoSPECT/CT for Oncology Research
-
批准号:7838795
-
项目类别:
-
资助金额:$90.73万
-
财政年份:2011
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:7102448
-
项目类别:
-
资助金额:$14.45万
-
财政年份:2006
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:9751795
-
项目类别:
-
资助金额:$14.41万
-
财政年份:--
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:9532118
-
项目类别:
-
资助金额:$14.45万
-
财政年份:--
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:8109178
-
项目类别:
-
资助金额:$31.34万
-
财政年份:--
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:7460813
-
项目类别:
-
资助金额:$29.68万
-
财政年份:--
-
负责人:PAT B ZANZONICO
-
依托单位:
Imaging and Radiochemistry Core
-
批准号:7798056
-
项目类别:
-
资助金额:$30.78万
-
财政年份:--
-
负责人:PAT B ZANZONICO
-
依托单位:
海外基金